biosciences

US Merck Snaps up Prometheus Biosciences for $10.8 Billion

Shares of Prometheus Biosciences soared on news that US drugs major Merck will acquire the company in an all-cash deal valued at roughly $200 per share, or $10.8 billion.

Tosoh Boosts Biosciences with Semba Buy

DuPont to Buy Dyadic Biotech Assets

Bayer and Dimension Collaborate on Hemophilia A

BASF Launches Inorganics-Focused California R&D Center

Baxter Profit Higher; Sales Seen Rising 10% in 2013